Genetic Biomarkers in Acute Myeloid Leukemia

Will the Promise of Improving Treatment Outcomes Be Realized?

Jay Yang; Charles A Schiffer


Expert Rev Hematol. 2012;5(4):395-407. 

In This Article

Other Mutations

A variety of other recurring mutations have been described in AML, most of which have a negative prognostic impact. Affected genes include ASXL1, NRAS, TP53, WT1, PHF6, RUNX1 and MLL-PTD.[51–55] Conclusions about the significance of these mutations cannot be made with great confidence due to their relative infrequency. In addition to mutational events, many other genes have been found to be either over- or under-expressed in AML and have associated prognostic value. Examples include MN1, BAALC, ERG, EVI1 and PRAME.[56–59]